{"id":59571,"date":"2026-03-16T14:05:44","date_gmt":"2026-03-16T06:05:44","guid":{"rendered":"https:\/\/flcube.com\/?p=59571"},"modified":"2026-03-16T14:05:44","modified_gmt":"2026-03-16T06:05:44","slug":"junshi-biosciences-reports-rmb-2-5-billion-2025-revenue-toripalimab-drives-40-drug-sales-growth-as-losses-narrow","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59571","title":{"rendered":"Junshi Biosciences Reports RMB 2.5\u202fBillion 2025 Revenue \u2013 Toripalimab Drives 40% Drug Sales Growth as Losses Narrow"},"content":{"rendered":"\n

Shanghai Junshi Biosciences Co., Ltd.<\/strong> (HKG: 1877<\/a>, SHA: 688180<\/a>) released 2025 financial results<\/strong>, recording RMB 2.498\u202fbillion (USD\u202f362\u202fmillion)<\/strong> in total revenue, up 28.32% year-on-year<\/strong>, with drug sales surging 40.32% to RMB 2.301\u202fbillion<\/strong>. The net loss narrowed 31.68% to RMB 875\u202fmillion<\/strong> as the company maintained RMB 1.342\u202fbillion in R&D investment<\/strong> across 90+ clinical studies<\/strong>. Core product toripalimab (Tuoyi)<\/strong> generated RMB 2.068\u202fbillion (up 38% YOY)<\/strong> with all 12 indications NRDL-listed<\/strong>, while new pipeline assets<\/strong> including subcutaneous toripalimab<\/strong>, roconkibart (IL-17A)<\/strong>, and multiple Phase III programs<\/strong> position Junshi for sustained growth and profitability inflection<\/strong>.<\/p>\n\n\n\n

Financial Performance Summary<\/h2>\n\n\n\n
Metric<\/th>2025 Result<\/th>Change (YOY)<\/th>Strategic Note<\/th><\/tr><\/thead>
Total Revenue<\/strong><\/td>RMB 2.498\u202fbn (USD\u202f362\u202fmn)<\/td>+28.32%<\/strong><\/td>Strong commercial momentum<\/td><\/tr>
Drug Sales Revenue<\/strong><\/td>RMB 2.301\u202fbn (USD\u202f333\u202fmn)<\/td>+40.32%<\/strong><\/td>Core driver of growth<\/td><\/tr>
Net Loss (Parent)<\/strong><\/td>RMB 875\u202fmn (USD\u202f127\u202fmn)<\/td>-31.68%<\/strong> (narrowed)<\/td>Path to profitability improving<\/td><\/tr>
R&D Investment<\/strong><\/td>RMB 1.342\u202fbn (USD\u202f194\u202fmn)<\/td>Sustained<\/td>90+ clinical studies ongoing<\/td><\/tr>
Overseas Revenue<\/strong><\/td>Significant growth<\/td>Expanding<\/td>Toripalimab approved in 40+ countries<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Core Product Performance<\/h2>\n\n\n\n
Product<\/th>2025 Sales<\/th>Growth (YOY)<\/th>Strategic Highlights<\/th><\/tr><\/thead>
Toripalimab (Tuoyi)<\/strong><\/td>RMB 2.068\u202fbn (USD\u202f299\u202fmn)<\/td>+38%<\/strong><\/td>\u2022 PD-1 mAb core franchise
\u2022 12 approved indications (all NRDL-listed)
\u2022 Approved in 40+ countries overseas
\u2022 Subcutaneous formulation in marketing application<\/td><\/tr>
Junshida (ongericimab)<\/strong><\/td>New launch<\/td>\u2014<\/td>\u2022 PCSK9 mAb
\u2022 First-time NRDL inclusion
\u2022 Two indications approved<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Pipeline Advancement<\/h2>\n\n\n\n
Asset<\/th>Class<\/th>Indication\/Status<\/th>Strategic Value<\/th><\/tr><\/thead>
Subcutaneous toripalimab<\/strong><\/td>PD-1 mAb (new formulation)<\/td>Marketing application stage<\/td>Convenience upgrade; potential market expansion<\/td><\/tr>
Roconkibart<\/strong><\/td>Anti-IL-17A mAb<\/td>Marketing application stage<\/td>Autoimmune diversification; psoriasis\/ankylosing spondylitis<\/td><\/tr>
JS107<\/strong><\/td>CLDN18.2 ADC<\/td>Phase III<\/td>Gastric cancer; next-gen oncology asset<\/td><\/tr>
JS207<\/strong><\/td>PD-1\/VEGF bispecific<\/td>China\/U.S. IND approved<\/td>Dual mechanism; potential best-in-class<\/td><\/tr>
JS212<\/strong><\/td>EGFR\/HER3 ADC<\/td>China\/U.S. IND approved<\/td>Targeted therapy for solid tumors<\/td><\/tr>
JS213<\/strong><\/td>PD-1\/IL-2 fusion<\/td>China\/U.S. IND approved<\/td>Immune activation enhancement<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Context & Market Position<\/h2>\n\n\n\n
Factor<\/th>Implication<\/th><\/tr><\/thead>
NRDL Leverage<\/strong><\/td>100% toripalimab indication coverage ensures broad access; ongericimab NRDL inclusion drives rapid uptake<\/td><\/tr>
Global Expansion<\/strong><\/td>40+ country approvals for toripalimab validate international quality standards; emerging market revenue diversification<\/td><\/tr>
Formulation Innovation<\/strong><\/td>Subcutaneous PD-1 addresses patient convenience; biosimilar defense strategy<\/td><\/tr>
Pipeline Depth<\/strong><\/td>90+ studies across oncology and immunology; multiple Phase III assets de-risk revenue concentration<\/td><\/tr>
Profitability Trajectory<\/strong><\/td>Loss narrowing + 40% drug sales growth suggests break-even potential 2027-2028<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Competitive Landscape<\/h2>\n\n\n\n
Competitor<\/th>Key Product<\/th>China Position<\/th>Junshi Differentiation<\/th><\/tr><\/thead>
BeiGene<\/strong><\/td>Tislelizumab<\/td>Leading PD-1<\/td>Toripalimab global approvals; formulation diversity<\/td><\/tr>
Hengrui<\/strong><\/td>Camrelizumab<\/td>Large oncology portfolio<\/td>Junshi focus on quality\/global expansion vs. volume<\/td><\/tr>
Innovent<\/strong><\/td>Sintilimab<\/td>NRDL price leader<\/td>Toripalimab 40+ country approvals; international revenue<\/td><\/tr>
Junshi<\/strong><\/td>Toripalimab + pipeline<\/strong><\/td>12 NRDL indications; 40+ global approvals<\/strong><\/td>First-mover subcutaneous PD-1; diversified autoimmune (IL-17A)<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Forward\u2011Looking Statements<\/strong>
This brief contains forward\u2011looking statements regarding profitability trajectory, pipeline advancement, and global expansion for Junshi Biosciences. Actual results may differ due to NRDL pricing pressures, competitive dynamics in PD-1\/IL-17A markets, and clinical trial outcomes.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) released 2025 financial results, recording RMB…<\/p>\n","protected":false},"author":1,"featured_media":59573,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[27,899,296,900],"class_list":["post-59571","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-finanical-reports","tag-hkg-1877","tag-junshi-biosciences","tag-sha-688180"],"yoast_head":"\nJunshi Biosciences Reports RMB 2.5\u202fBillion 2025 Revenue \u2013 Toripalimab Drives 40% Drug Sales Growth as Losses Narrow - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) released 2025 financial results, recording RMB 2.498\u202fbillion (USD\u202f362\u202fmillion) in total revenue, up 28.32% year-on-year, with drug sales surging 40.32% to RMB 2.301\u202fbillion. The net loss narrowed 31.68% to RMB 875\u202fmillion as the company maintained RMB 1.342\u202fbillion in R&D investment across 90+ clinical studies. Core product toripalimab (Tuoyi) generated RMB 2.068\u202fbillion (up 38% YOY) with all 12 indications NRDL-listed, while new pipeline assets including subcutaneous toripalimab, roconkibart (IL-17A), and multiple Phase III programs position Junshi for sustained growth and profitability inflection.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=59571\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Junshi Biosciences Reports RMB 2.5\u202fBillion 2025 Revenue \u2013 Toripalimab Drives 40% Drug Sales Growth as Losses Narrow\" \/>\n<meta property=\"og:description\" content=\"Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) released 2025 financial results, recording RMB 2.498\u202fbillion (USD\u202f362\u202fmillion) in total revenue, up 28.32% year-on-year, with drug sales surging 40.32% to RMB 2.301\u202fbillion. The net loss narrowed 31.68% to RMB 875\u202fmillion as the company maintained RMB 1.342\u202fbillion in R&D investment across 90+ clinical studies. Core product toripalimab (Tuoyi) generated RMB 2.068\u202fbillion (up 38% YOY) with all 12 indications NRDL-listed, while new pipeline assets including subcutaneous toripalimab, roconkibart (IL-17A), and multiple Phase III programs position Junshi for sustained growth and profitability inflection.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=59571\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-16T06:05:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1603.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59571#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59571\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Junshi Biosciences Reports RMB 2.5\u202fBillion 2025 Revenue \u2013 Toripalimab Drives 40% Drug Sales Growth as Losses Narrow\",\"datePublished\":\"2026-03-16T06:05:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59571\"},\"wordCount\":457,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59571#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1603.webp\",\"keywords\":[\"Finanical Reports\",\"HKG: 1877\",\"Junshi Biosciences\",\"SHA: 688180\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59571#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59571\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=59571\",\"name\":\"Junshi Biosciences Reports RMB 2.5\u202fBillion 2025 Revenue \u2013 Toripalimab Drives 40% Drug Sales Growth as Losses Narrow - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59571#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59571#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1603.webp\",\"datePublished\":\"2026-03-16T06:05:44+00:00\",\"description\":\"Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) released 2025 financial results, recording RMB 2.498\u202fbillion (USD\u202f362\u202fmillion) in total revenue, up 28.32% year-on-year, with drug sales surging 40.32% to RMB 2.301\u202fbillion. The net loss narrowed 31.68% to RMB 875\u202fmillion as the company maintained RMB 1.342\u202fbillion in R&D investment across 90+ clinical studies. Core product toripalimab (Tuoyi) generated RMB 2.068\u202fbillion (up 38% YOY) with all 12 indications NRDL-listed, while new pipeline assets including subcutaneous toripalimab, roconkibart (IL-17A), and multiple Phase III programs position Junshi for sustained growth and profitability inflection.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59571#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59571\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59571#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1603.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1603.webp\",\"width\":1080,\"height\":608,\"caption\":\"Junshi Biosciences Reports RMB 2.5\u202fBillion 2025 Revenue \u2013 Toripalimab Drives 40% Drug Sales Growth as Losses Narrow\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59571#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Junshi Biosciences Reports RMB 2.5\u202fBillion 2025 Revenue \u2013 Toripalimab Drives 40% Drug Sales Growth as Losses Narrow\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Junshi Biosciences Reports RMB 2.5\u202fBillion 2025 Revenue \u2013 Toripalimab Drives 40% Drug Sales Growth as Losses Narrow - Insight, China's Pharmaceutical Industry","description":"Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) released 2025 financial results, recording RMB 2.498\u202fbillion (USD\u202f362\u202fmillion) in total revenue, up 28.32% year-on-year, with drug sales surging 40.32% to RMB 2.301\u202fbillion. The net loss narrowed 31.68% to RMB 875\u202fmillion as the company maintained RMB 1.342\u202fbillion in R&D investment across 90+ clinical studies. Core product toripalimab (Tuoyi) generated RMB 2.068\u202fbillion (up 38% YOY) with all 12 indications NRDL-listed, while new pipeline assets including subcutaneous toripalimab, roconkibart (IL-17A), and multiple Phase III programs position Junshi for sustained growth and profitability inflection.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=59571","og_locale":"en_US","og_type":"article","og_title":"Junshi Biosciences Reports RMB 2.5\u202fBillion 2025 Revenue \u2013 Toripalimab Drives 40% Drug Sales Growth as Losses Narrow","og_description":"Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) released 2025 financial results, recording RMB 2.498\u202fbillion (USD\u202f362\u202fmillion) in total revenue, up 28.32% year-on-year, with drug sales surging 40.32% to RMB 2.301\u202fbillion. The net loss narrowed 31.68% to RMB 875\u202fmillion as the company maintained RMB 1.342\u202fbillion in R&D investment across 90+ clinical studies. Core product toripalimab (Tuoyi) generated RMB 2.068\u202fbillion (up 38% YOY) with all 12 indications NRDL-listed, while new pipeline assets including subcutaneous toripalimab, roconkibart (IL-17A), and multiple Phase III programs position Junshi for sustained growth and profitability inflection.","og_url":"https:\/\/flcube.com\/?p=59571","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-16T06:05:44+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1603.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=59571#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=59571"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Junshi Biosciences Reports RMB 2.5\u202fBillion 2025 Revenue \u2013 Toripalimab Drives 40% Drug Sales Growth as Losses Narrow","datePublished":"2026-03-16T06:05:44+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=59571"},"wordCount":457,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=59571#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1603.webp","keywords":["Finanical Reports","HKG: 1877","Junshi Biosciences","SHA: 688180"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=59571#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=59571","url":"https:\/\/flcube.com\/?p=59571","name":"Junshi Biosciences Reports RMB 2.5\u202fBillion 2025 Revenue \u2013 Toripalimab Drives 40% Drug Sales Growth as Losses Narrow - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=59571#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=59571#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1603.webp","datePublished":"2026-03-16T06:05:44+00:00","description":"Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) released 2025 financial results, recording RMB 2.498\u202fbillion (USD\u202f362\u202fmillion) in total revenue, up 28.32% year-on-year, with drug sales surging 40.32% to RMB 2.301\u202fbillion. The net loss narrowed 31.68% to RMB 875\u202fmillion as the company maintained RMB 1.342\u202fbillion in R&D investment across 90+ clinical studies. Core product toripalimab (Tuoyi) generated RMB 2.068\u202fbillion (up 38% YOY) with all 12 indications NRDL-listed, while new pipeline assets including subcutaneous toripalimab, roconkibart (IL-17A), and multiple Phase III programs position Junshi for sustained growth and profitability inflection.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=59571#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=59571"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=59571#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1603.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1603.webp","width":1080,"height":608,"caption":"Junshi Biosciences Reports RMB 2.5\u202fBillion 2025 Revenue \u2013 Toripalimab Drives 40% Drug Sales Growth as Losses Narrow"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=59571#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Junshi Biosciences Reports RMB 2.5\u202fBillion 2025 Revenue \u2013 Toripalimab Drives 40% Drug Sales Growth as Losses Narrow"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1603.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59571","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=59571"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59571\/revisions"}],"predecessor-version":[{"id":59574,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59571\/revisions\/59574"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/59573"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=59571"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=59571"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=59571"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}